Table 3 Standardized incidence ratios (SIRs) and 95% confidence intervals (CIs) in dialysis patients for selected de novo malignancies (DNMs). Friuli Venezia Giulia, north-eastern Italy, 1998–2013
Totala | ||||
|---|---|---|---|---|
Cancer type/site | ICD-9 codes | Obs. | Exp. | SIR (95% CI) |
All but skin non-melanomab | 249 | 213.7 | 1.17 (1.03–1.32) | |
Skin non-melanoma | 173 | 93 | 51.3 | 1.81 (1.46–2.22) |
Prostate | 185 | 35 | 39.5 | 0.89 (0.62–1.23) |
Trachea, bronchus, and lung | 162 | 31 | 28.4 | 1.09 (0.74–1.55) |
Colon, rectum, and anus | 153, 154 | 27 | 31.7 | 0.85 (0.56–1.24) |
Kidney | 189 | 25 | 7.9 | 3.18 (2.06–4.69) |
Bladder | 188 | 16 | 17.0 | 0.94 (0.54–1.52) |
Oral cavity | 140–149 | 15 | 6.2 | 2.42 (1.36–4.00) |
Stomach | 151 | 14 | 11.6 | 1.20 (0.66–2.02) |
Liver | 155 | 14 | 9.2 | 1.53 (0.83–2.56) |
Female breast | 174 | 13 | 14.9 | 0.81 (0.42–1.41) |
Melanoma | 172 | 9 | 5 | 1.81 (0.83–3.43) |
Pancreas | 157 | 7 | 7.5 | 0.93 (0.38–1.93) |
Larynx | 161 | 7 | 3.4 | 2.03 (0.82–4.18) |
Other and ill-defined sites | 195 | 7 | 1 | 7.31 (2.94–15.07) |
Malignant neoplasm without site specification | 199 | 7 | 3.8 | 1.86 (0.75–3.84) |
Multiple myeloma | 203 | 5 | 2.9 | 1.72 (0.56–4.02) |
Leukemia | 204–208 | 4 | 4.2 | 0.95 (0.26–2.43) |
Corpus uteri | 182 | 4 | 2.1 | 1.94 (0.53–4.96) |
Pleura | 163 | 2 | 1.8 | 1.11 (0.13–4.00) |
Other and ill-defined sites within the respiratory system | 165 | 2 | 0.6 | 3.14 (0.38–11.33) |
Connective and other soft tissue | 171 | 2 | 1.1 | 1.90 (0.23–6.87) |
Kaposi’s sarcoma | 176 | 2 | 0.2 | 10.29 (1.25–37.16) |
Uterus, unspecified | 179 | 2 | 0.3 | 7.0 (0.85–25.30) |
Thyroid gland | 193 | 2 | 1.4 | 1.39 (0.17–5.01) |
Non-Hodgkin lymphoma | 200,202 | 2 | 6.6 | 0.30 (0.04–1.10) |